Curasight caps 2024 with financing push
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Nyhet

Curasight caps 2024 with financing push

Curasight caps 2024 with financing push

Reporting the fourth quarter, financing is high on the agenda for danish Curasight.

With the prostate cancer study ongoing with uTRACE, the company targets mid 2025 for the start of the first clinical study with the thrapeutics platform uTREAT, in brain cancer. BioStock reached out to CEO Ulrich Krasilnikoff to learn more.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

Denna källa har få eller inga artiklar bakom betalvägg
Läs hela artikeln hos Biostock

Nyhetsbrev